C4 TherapeuticsvsJohnson & Johnson

CCCC and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CCCC

C4 Therapeutics, Inc.

$2.65

Value $348M

-3.99%
CCCC's page

C4 Therapeutics (CCCC) has a market value of $348M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, CCCC moved +7.3% and JNJ +47.5%. Dividend yield: CCCC none, JNJ 1.87%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CCCC$348M

    JNJ$681B

    JNJ is 1,957 times CCCC

  • Revenue, 12 months

    CCCC$32M

    JNJ$99.3B

    JNJ is 3,078 times CCCC

  • Net income, 12 months

    CCCC-$91M

    JNJ$16.1B

  • Operating margin

    CCCC-315.9%

    JNJ–

  • ROIC

    CCCC-35.9%

    JNJ12.4%

    48.3 points apart

  • P/E

    CCCC–

    JNJ42.3

  • Dividend yield

    CCCC0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    CCCC-93.6%

    JNJ+98.6%

    192.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CCCC-93.6%

JNJ+98.6%

010020020222023202420252026
Returns by period
PeriodCCCCWith dividendsJNJWith dividends
1 year since November 14, 2025+7.3%Price +7.3%+47.5%Price +44.2%
3 years since November 16, 2023+45.6%+13.3% a yearPrice +45.6%+105.0%+27.0% a yearPrice +88.2%
5 years since November 15, 2021-93.6%-42.4% a yearPrice -93.6%+98.6%+14.7% a yearPrice +72.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CCCCC4 TherapeuticsJNJJohnson & Johnson

Valuation

CCCCJNJ
Valuation
Price$2.65$282.55
Market value$348M$681B
Enterprise value (EV)$73M$708B
P/E–42.3
P/E, 5-year median–21.9
P/B1.58.4
EV/EBIT–39.9
Free cash flow yield–3.0%

Results and growth

CCCCJNJ
Results and growth
Revenue, 12 months$32M$99.3B
Net income, 12 months-$91M$16.1B
Free cash flow, 12 months-$80M$20.6B
Earnings per share, 12 months-$0.63$6.59
Revenue growth, year on year1.0%6.1%
Revenue growth a year, past-5.9%over 4 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CCCCJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-315.9%–
Net margin-282.2%16.2%
ROIC-35.9%12.4%
ROE-40.6%19.7%

Balance sheet

CCCCJNJ
Balance sheet
Cash$275M$17.2B
Total debt$55M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

CCCCJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield0.1%0.9%
Shareholder yield0.1%2.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CCCC or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, C4 Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($681B) is about 1,956.7 times C4 Therapeutics ($348M), at today's prices.

How did CCCC and JNJ stock do over the last 5 years?

Since November 15, 2021, CCCC's price moved -93.6% and JNJ's +72.8%. With dividends: CCCC -93.6% (-42.4% a year), JNJ +98.6% (+14.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, CCCC or JNJ?

The dividend yield at today's price is none for C4 Therapeutics and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, C4 Therapeutics or Johnson & Johnson?

Over the last twelve months, the net margin was -282.2% for C4 Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -315.9% and –. Revenue was $32M and $99.3B.

Which is the better investment, C4 Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.